2026 Stephen B. Hanauer: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	144	1408	1301	822	747	988	111582

Overview

Stephen B. Hanauer is affiliated with Northwestern University in the United States. Their research spans multiple fields within medicine and biological sciences, with a particular focus on gastrointestinal disorders and immune-related diseases.

The scientist's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, key subfields of their work are Genetics, Epidemiology, Immunology, Surgery, and Oncology.

The primary topics covered in their research consist of:

Inflammatory Bowel Disease
Microscopic Colitis
Biosimilars and Bioanalytical Methods
Immunodeficiency and Autoimmune Disorders
Eosinophilic Esophagitis
Cancer Immunotherapy and Biomarkers
Liver Diseases and Immunity

Stephen B. Hanauer has contributed to a significant number of publications in leading journals within their field. The most frequent publication venues are:

Gastroenterology (48 publications)
Journal of Crohn's and Colitis (30 publications)
The American Journal of Gastroenterology (26 publications)
Inflammatory Bowel Diseases (21 publications)
Clinical Gastroenterology and Hepatology (6 publications)

The scientist has collaborated extensively with several researchers, including:

Silvio Danese (55 co-authored works)
William J. Sandborn (44 co-authored works)
Bruce E. Sands (32 co-authored works)
Jean-Frédéric Colombel (31 co-authored works)
Stefan Schreiber (29 co-authored works)

Some of their recent papers reflect ongoing interests in therapeutic interventions and clinical management of inflammatory bowel diseases and related conditions. These papers include:

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis, 2021, New England Journal of Medicine
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial, 2022, The Lancet
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial, 2021, Clinical Gastroenterology and Hepatology
Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting, 2020, Gastroenterology
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study, 2021, Journal for ImmunoTherapy of Cancer

Best Publications

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

Yasunori Ogura;Denise K. Bonen;Naohiro Inohara;Dan L. Nicolae

6168
Citations
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer

5145
Citations
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

S. R. Targan;S. B. Hanauer;S. J. H. Van Deventer;L. Mayer

4986
Citations
Infliximab for induction and maintenance therapy for ulcerative colitis.

Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch

4536
Citations
Infliximab for the treatment of fistulas in patients with Crohn's disease.

D.H. Present;P.J. Rutgeerts;S.R. Targan;S.B. Hanauer

3464
Citations
Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer

2736
Citations
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns

2681
Citations
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer

2472
Citations
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy

Simon Lichtiger;Daniel H. Present;Asher Kornbluth;Irwin Gelernt

2312
Citations
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak

2050
Citations
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

1770
Citations
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

Geert D’Haens;William J. Sandborn;Brian G. Feagan;Karel Geboes

1585
Citations
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

Christoph Gasche;Jurgen Scholmerich;Jorn Brynskov;Geert D'Haens

1465
Citations
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.

Stephen B Hanauer

1421
Citations
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Paul Rutgeerts;G D'Haens;S Targan;E Vasiliauskas

1339
Citations
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

William J. Sandborn;Stephen B. Hanauer;Seymour Katz;Michael Safdi

1320
Citations
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

Stefan Schreiber;Mani Khaliq-Kareemi;Ian C. Lawrance;Ole Østergaard Thomsen

1303
Citations
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak

1271
Citations
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

William J. Sandborn;Paul Rutgeerts;Robert Enns;Stephen B. Hanauer

1253
Citations
Management of Crohn's Disease in Adults

Gary R Lichtenstein;Stephen B Hanauer;Stephen B Hanauer;Stephen B Hanauer;William J Sandborn;William J Sandborn;William J Sandborn

1221
Citations

Frequent Co-Authors

William J. Sandborn University of California, San Diego

Brian G. Feagan University of Western Ontario

Paul Rutgeerts KU Leuven

Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai

David T. Rubin University of Chicago

Bruce E. Sands Icahn School of Medicine at Mount Sinai

Subrata Ghosh University College Cork

Gary R. Lichtenstein University of Pennsylvania

Stefan Schreiber Kiel University

Walter Reinisch Medical University of Vienna

External Links

Personal website of Stephen B. Hanauer

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always follow a traditional path. Many students and professionals consider related online degrees to diversify or specialize their expertise. For those interested in mental health, online msn pmhnp programs offer a flexible way to become a Psychiatric Mental Health Nurse Practitioner, meeting the high demand for mental health providers.

Healthcare administration is another rapidly growing field. Earning healthcare administration degrees online can lead to management or leadership roles in hospitals, clinics, or insurance companies. Cost is a major factor for many students, making it important to compare the masters in healthcare administration cost before enrolling.

For nurses seeking to reach the highest level of clinical practice, the best online bsn to dnp programs allow working professionals to study remotely and advance their qualifications. These career pathways offer flexibility, affordability, and a wide range of options for those passionate about healthcare, both in clinical and non-clinical roles.